Dupilumab, a monoclonal antibody targeting the α subunit of the Interleukin-4 Receptor (IL-4Rα), blocks IL-4 and IL-13 signaling and has been proposed as a potential treatment for localized scleroderma.2 This evidence concerns the gene IL4 and localized scleroderma.